reports
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Con...
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Piper Sandler 37th Annual Healthcare Conference in New York City. Participating will be Ben Zeskind, Co-founder and Chief Executive Officer, Igor Matushansky M.D., Chief Medical Officer, Harold “E.B.” Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Off...
Immuneering Reports Third Quarter 2025 Financial Results and Provides ...
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates - Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million private placement with Sanofi - - Cash runway extended into 2029, including through topline readout of planned Phase 3 trial of atebimetinib + mGnP in first-line pancreatic cancer - - Granted U.S. composition of matter patent for atebimetinib that is expected to provide exclusivity into 2042 - - New...
- Laura Chico
- Thomas Yip
Immuneering to Report Third Quarter 2025 Financial Results and Provide...
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 - New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday, November 12, 2025, at 4:30 pm ET - NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that the company will report third quarter 2025 financ...
- Jonathan Moreland
VIRC VIRCO MANUFACTURING CORP.
THFF FIRST FINANCIAL CORP. (INDIANA)
SSNC SS&C TECHNOLOGIES HOLDINGS INC.
PNFP PINNACLE FINANCIAL PARTNERS INC.
FDS FACTSET RESEARCH SYSTEMS INC.
DENN DENNY'S CORPORATION
CNS COHEN & STEERS INC.
CMC COMMERCIAL METALS COMPANY
CAPL CROSSAMERICA PARTNERS LP
CAG CONAGRA BRANDS INC.
ANGO ANGIODYNAMICS INC.
ASA ASA
ADC AGREE REALTY CORPORATION
ATRO ASTRONICS CORPORATION
RVP RETRACTABLE TECHNOLOGIES INC.
TRT TRIO TECH INTERNATIONAL
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
FBK FB FINANCIAL CORPORATION
GRF EAGLE CAPITAL GROWTH FUND INC
GWRS GLOBAL WATER RESOURCES
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
BRT BRT APARTMENTS
ZIVO ZIVO BIOSCIENCE
CPSH INC.
STRO CPS TECHNOLOGIES
GRX SUTRO BIOPHARMA
PNTG THE GABELLI HEALTHCARE & WELLNESSRX TRUST
PCB PENNANT GROUP
WWR PACIFIC CITY FINANCIAL CORP
ACET WESTWATER RESOURCES
CGEM ADICET BIO INC
SMMT CULLINAN ONCOLOGY INC
INTA SUMMIT THERAPEUTICS INC
IMRX INTAPP INC
REFI IMMUNEERING CORP
VANI CHICAGO ATLANTIC REAL ESTATE FINANCE INC
EP VIVANI MEDICAL INC
SOC EMPIRE PETROLEUM CORP
LAW SABLE OFFSHORE CORP
HYMC CS DISCO INC
NUGN HYCROFT MINING HOLDING CORPORATION
LIVENTO GROUP
INC.
- Jonathan Moreland
VIRC VIRCO MANUFACTURING CORP.
THFF FIRST FINANCIAL CORP. (INDIANA)
SSNC SS&C TECHNOLOGIES HOLDINGS INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
FDS FACTSET RESEARCH SYSTEMS INC.
CAPL CROSSAMERICA PARTNERS LP
CALM CAL-MAINE FOODS INC.
CAG CONAGRA BRANDS INC.
ANGO ANGIODYNAMICS INC.
ASA ASA
ADC AGREE REALTY CORPORATION
RIGN TRANSOCEAN LTD.
RVP RETRACTABLE TECHNOLOGIES INC.
TRT TRIO TECH INTERNATIONAL
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
AMBC AMBAC FINANCIAL GROUP INC.
GWRS GLOBAL WATER RESOURCES
BRT BRT APARTMENTS
ZIVO ZIVO BIOSCIENCE
CPSH INC.
FUND CPS TECHNOLOGIES
FGBI ROYCE FOCUS TRUST
STRO INC.
SAVA FIRST GUARANTY BANCSHARES
DX SUTRO BIOPHARMA
PNTG CASSAVA SCIENCES
PCB DYNEX CAPITAL INC.
WWR PENNANT GROUP
ACET PACIFIC CITY FINANCIAL CORP
ALTM WESTWATER RESOURCES
CGEM ADICET BIO INC
OPEN ALTUS MIDSTREAM COMPANY (A)
GGZ CULLINAN ONCOLOGY INC
IMRX OPENDOOR TECHNOLOGIES INC.
REFI GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST
PEPG IMMUNEERING CORP
VANI CHICAGO ATLANTIC REAL ESTATE FINANCE INC
UAMY PEPGEN INC
SOC VIVANI MEDICAL INC
LAW U S ANTIMONY CORP
MRAI SABLE OFFSHORE CORP
HYMC CS DISCO INC
SABS MARPAI
INC.
HYCROFT MINING HOLDING CORPORATION
BIG CYPRESS ACQUISITION CORP.
- Jonathan Moreland
WOR WORTHINGTON INDUSTRIES INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
FDS FACTSET RESEARCH SYSTEMS INC.
CALM CAL-MAINE FOODS INC.
CAG CONAGRA BRANDS INC.
ANGO ANGIODYNAMICS INC.
KRNY KEARNY FINANCIAL CORP.
ADC AGREE REALTY CORPORATION
CULP CULP INC.
RIGN TRANSOCEAN LTD.
RVP RETRACTABLE TECHNOLOGIES INC.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
AMBC AMBAC FINANCIAL GROUP INC.
HAIN THE HAIN CELESTIAL GROUP
GWRS INC.
AROC GLOBAL WATER RESOURCES
ZIVO ARCHROCK INC.
CPSH ZIVO BIOSCIENCE
FUND INC.
ARVN CPS TECHNOLOGIES
FGBI ROYCE FOCUS TRUST
BCDA INC.
SAVA ARVINAS HOLDING
DX FIRST GUARANTY BANCSHARES
AOUT BIOCARDIA
ACET CASSAVA SCIENCES
ALTM DYNEX CAPITAL INC.
CGEM AMERICAN OUTDOOR BRANDS
OPEN INC.
GGZ ADICET BIO INC
IMRX ALTUS MIDSTREAM COMPANY (A)
ABSI CULLINAN ONCOLOGY INC
PEPG OPENDOOR TECHNOLOGIES INC.
MRVL GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST
UAMY IMMUNEERING CORP
PRAX ABSCI CORP
LAW PEPGEN INC
MRAI MARVEL BIOSCIENCES CORP
JSPR U S ANTIMONY CORP
BDSX PRAXIS PRECISION MEDICINES INC
SABS CS DISCO INC
MARPAI
INC.
AMPLITUDE HEALTHCARE ACQUISITION CORP
BIODESIX INC
BIG CYPRESS ACQUISITION CORP.
- Jonathan Moreland
- Jonathan Moreland
WOR WORTHINGTON INDUSTRIES INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
NMFC NEW MOUNTAIN FINANCE CORPORATION
NGL NGL ENERGY PARTNERS LP
KRNY KEARNY FINANCIAL CORP.
ADC AGREE REALTY CORPORATION
CULP CULP INC.
RIGN TRANSOCEAN LTD.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
AMBC AMBAC FINANCIAL GROUP INC.
HAIN THE HAIN CELESTIAL GROUP
SMRT INC.
MBIN SMARTSPACE SOFTWARE
AROC MERCHANTS BANCORP
FUND ARCHROCK INC.
ARVN ROYCE FOCUS TRUST
FGBI INC.
BCDA ARVINAS HOLDING
UUU FIRST GUARANTY BANCSHARES
SAVA BIOCARDIA
DX UNIVERSAL SECURITY INSTRUMENTS INC.
AOUT CASSAVA SCIENCES
ALXO DYNEX CAPITAL INC.
ALTM AMERICAN OUTDOOR BRANDS
AMR INC.
OPEN ALX ONCOLOGY HOLDINGS
GGZ ALTUS MIDSTREAM COMPANY (A)
IMRX ALPHA METALLURGICAL RESOURCES INC
ABSI OPENDOOR TECHNOLOGIES INC.
RYAN GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST
PEPG IMMUNEERING CORP
MRVL ABSCI CORP
BUKS RYAN SPECIALTY GROUP HLDGS INC
OBLG PEPGEN INC
VANI MARVEL BIOSCIENCES CORP
UAMY BUTLER NATIONAL CORP
PRAX OBLONG INC
NCDL VIVANI MEDICAL INC
NEXT U S ANTIMONY CORP
MRAI PRAXIS PRECISION MEDICINES INC
JSPR NUVEEN CHURCHILL DIRECT LENDING CORP
BDSX NEXTSOURCE MATERIALS INC.
SABS MARPAI
INC.
AMPLITUDE HEALTHCARE ACQUISITION CORP
BIODESIX INC
BIG CYPRESS ACQUISITION CORP.
- Jonathan Moreland
- Jonathan Moreland
- Wedbush Research
TRIP TRIPADVISOR INC.
EXPE EXPEDIA GROUP INC.
NFLX NETFLIX INC.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
BKNG BOOKING HOLDINGS INC.
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
LRMR LARIMAR THERAPEUTICS INC
U UNITY SOFTWARE
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
RBLX ROBLOX
APP APPLOVIN CORP
YOU CLEAR SECURE INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
PEPG PEPGEN INC
- Laura Chico
- Seth Basham
Immuneering to Discuss Recently Announced Overall Survival Data from P...
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + m...
- Wedbush Research
CYBR CYBERARK SOFTWARE LTD.
BCRX BIOCRYST PHARMACEUTICALS INC.
MSFT MICROSOFT CORPORATION
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
BDTX BLACK DIAMOND THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
COGT COGENT BIOSCIENCES INC
PHVS PHARVARIS NV
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
TNGX TANGO THERAPEUTICS
ATXS INC
TYRA ASTRIA THERAPEUTICS INC
PEPG TYRA BIOSCIENCES INC
NUVL PEPGEN INC
BBOT NUVALENT INC
BRIDGEBIO ONCOLOGY THERAPEUTICS
Immuneering Announces Pricing of $175 Million Underwritten Public Offe...
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public offering of 18,959,914 shares of its Class A common stock at an offering price of $9.23 per share, which is equal to the last reported sale price for Immuneering’s Class A common stock on The Nasdaq Gl...
Immuneering Announces Proposed Underwritten Public Offering of Class A...
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offering of shares of its Class A common stock or, in lieu of Class A common stock, pre-funded warrants to purchase Class A common stock (the “Offering”). In addition, Immuneerin...
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months i...
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory feedback on pivotal trial plans in Q4 2025 and, subject to that feedback, expects to initiate pivotal trial by the end of 2025 and begin dosing patients by mid-2026 - NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.